Pulmonary embolism and deep vein thrombosis caused by nitrous oxide abuse: A case report

Wen Sun, Ji-Ping Liao, Yan Hu, Wei Zhang, Jing Ma, Guang-Fa Wang

ORCID number: Wen Sun (0000-0002-9209-4889); Ji-Ping Liao (0000-0003-2007-1917); Yan Hu (0000-0003-1908-4892); Wei Zhang (0000-0001-8091-1134); Jing Ma (0000-0003-3902-0917); Guang-Fa Wang (0000-0001-5949-2124).

Author contributions: All authors contributed to the acquisition of data and the writing and revision of the manuscript.

Informed consent statement: Consent was obtained from the patient for publication of this report and any accompanying images.

Conflict-of-interest statement: All the authors declare that they have no conflict of interest.

CARE Checklist (2016) statement: The manuscript was prepared and revised according to the CARE Checklist (2016).

Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

Manuscript source: Unsolicited manuscript

Abstract

BACKGROUND
Nitrous oxide (N2O) has gained increasing popularity as a recreational drug, causing hallucinations, excitation, and psychological dependence. However, side effects have been reported in recent years. Our case report proposes a correlation among N2O, pulmonary embolism (PE), and deep vein thrombosis (DVT) and emphasizes the role of homocysteine (Hcy) in thrombotic events.

CASE SUMMARY
A 29-year-old man with long-term N2O abuse sought evaluation after acute chest pain. A diagnostic workup revealed PE, DVT, and hyperhomocysteinemia. The patient was successfully treated with thrombolytic and anticoagulant therapy. Moreover, his Hcy level decreased and returned to normal after Hcy-lowering therapy.

CONCLUSION
Chronic N2O abuse might increase the risk of PE and DVT, although there have been few studies previously.

Key words: Nitrous oxide; Pulmonary embolism; Deep vein thrombosis; Homocysteine; Case report

©The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved.

Core tip: Pulmonary embolism and deep vein thrombosis arising from nitrous oxide use are extremely rare, although the mechanism seems reasonable, and few cases have been reported. In this case, chronic nitrous oxide abuse might be a direct or an indirect factor contributing to pulmonary embolism and deep vein thrombosis. Moreover, the treatment is unknown, and the prognosis is uncertain. Thus, we report this rare case and include a detailed discussion.
INTRODUCTION
Nitrous oxide (N₂O) is a small and simple inorganic chemical molecule that has been used for more than 150 years in clinical practice due to its analgesic, anxiolytic, and anesthetic properties[1].

Pulmonary embolism (PE) refers to obstruction of the pulmonary artery or one of its branches by an embolus such as a thrombus, tumor, air, or fat. Together with deep vein thrombosis (DVT), PE is a form of venous thromboembolism (VTE) that is common and sometimes fatal in acute situations or disabling in the chronic phase[2].

N₂O is correlated with hyperhomocysteinemia (HHcy) to some extent, and the latter has been found to be a potential risk factor for VTE. To the best of our knowledge, there are only a few reports of PE and DVT that were possibly triggered by HHcy secondary to N₂O use.

CASE PRESENTATION
Chief complaints
Sudden-onset chest pain for 1 d.

History of present illness
A 29-year-old man complained of sudden precordial pain with no remission for 1 d prior to hospital admission but denied hemoptysis, dyspnea, or syncope. He sought evaluation and was admitted for the purpose of intensive examination and treatment.

History of past illness
The patient had been addicted to N₂O for 1 year; as a result, peripheral neuropathy had occurred and was treated with vitamin B12 (Vit B₁₂). His medical history included poor blood glucose control and anxiety. However, he had no history of thrombosis, malignant tumor, recent trauma, or prolonged air travel.

Personal and family history
The patient has smoked over 13 pack-years and did not have alcoholism or a positive family history.

Physical examination upon admission
The initial assessment revealed that the patient was overweight and fragile, with a body mass index of 31.12 kg/m², temperature of 36.3 °C, blood pressure of 110-120/70-80 mmHg, heart rate over 110 beats/min, respiratory rate over 30 breaths/min, and pulse oximetry of 93% when the fraction of inspired oxygen was 49%. Moreover, the physical examination indicated diminished breath sounds on both sides and the accentuation of pulmonic second sounds.

Laboratory examinations
Laboratory data showed a high leukocyte count and an increased hemoglobin level, suggested abnormal liver biochemistry and hyperlipidemia, and revealed HHcy (24.12 µmol/L), high Vit B₁₂ (734 µmol/L), and normal folate (14.39 nmol/L). The results of the protein S, protein C, anti-thrombin III antibody, anti-cardiolipin antibody, lupus anticoagulant, anti-β2gp1 autoantibody, and other autoantibodies were within normal limits. The clotting profile was normal, other than the D-dimer value (1.13 mg/L), and thrombophilia screening was negative. As markers in the risk stratification of PE, the levels of brain natriuretic peptide (BNP) and cardiac troponin I (CTnI) were 533 pg/mL and 0.334 ng/mL, respectively. Arterial blood gas levels measured with an oxygen concentration of 49% showed the following: pH, 7.44; PaCO₂, 30 mmHg; and PaO₂, 74 mmHg.

Imaging examinations
An electrocardiogram (ECG, Figure 1A) showed sinus tachycardia with typical...
changes on SIQIIITIII (S wave in the aVL lead, Q wave and T wave in the III lead). Ultrasound cardiogram demonstrated right ventricular enlargement with left ventricular compression. Color Doppler scans were used to explore femoral, popliteal, and calf muscular venous thrombosis in the right extremity. Computed tomographic pulmonary angiography (CTPA) revealed occlusion of the pulmonary artery trunk, lobar artery, and arterial branches on both sides and signs of increased right heart load (Figure 2A and 2B).

**FINAL DIAGNOSIS**
Moderate-high risk PE and DVT along with N₂O abuse.

**TREATMENT**
The patient received a diagnosis of acute massive PE and newly discovered proximal and distal DVT, which was treated with a half dose of alteplase (50 mg) intravenously over two hours and anticoagulant therapy, and the HHcy was treated with folate.

**OUTCOME AND FOLLOW-UP**
After treatment, the laboratory parameters, including D-dimer, CTnI, BNP, and HCY levels, approached normal levels, the abnormal ECG waves disappeared on re-examination (Figure 1B), the areas of embolization were reduced on repeat CTPA (Figure 2C and Figure 2D) and finally disappeared, but the old lower extremity thrombosis still existed. Our patient was no longer taking N₂O in regular follow-up.

**DISCUSSION**
Research reports on the correlation between N₂O and VTE are very rare, although the mechanism seems reasonable. Chronic N₂O abuse is known to decrease active VitB₁₂ levels, inhibit methionine synthase, which plays a key role in the metabolism of methionine and folate, and eventually result in HHcy and thrombosis[3]. In a case of aortic arch thrombus caused by N₂O, the HCY level was decreased when N₂O use was stopped and then increased upon N₂O reuse[4].

N₂O may be one of the initial factors that caused PE. Previous research[5] supported that elimination of N₂O from the inspired gas rapidly reduced pulmonary artery pressure, decreased wasted ventilation, and increased cardiac output in non-lethal venous air embolism. However, the data are insufficient to perform a meta-analysis on the relationship between N₂O and PE[6], and ENIGMA-II trials showed that the number of acute HHcy cases after N₂O exposure was negligible[7]. This obvious inconsistency may be due to different entrance conditions and a lower concentration and shorter duration of N₂O in such trials.

HHcy has been found to be an intermediate factor for arterial and venous thrombosis[8-10]. As a potential risk factor for cardiovascular disease, HHcy may cause endothelium dysfunction, platelet and clotting activation, impaired fibrinolysis, and a shift of the balance of methylation[11-12]. Meanwhile, the relative risk for VTE in patients with HHcy is 2.5-2.95 that of the normal population[13-14]. Approximately 25% of patients with VTE have HHcy. In contrast, approximately one-third of HHcy patients subsequently develop VTE, and these patients have a 3.99-fold increased risk for PE[15].

HHcy may also be a risk factor for recurrent VTE. A multicenter study[16] prospectively followed patients with single idiopathic VTE after oral anticoagulant withdrawal and found that HHcy patients were more likely to have recurrent VTE than those with normal Hcy levels. In addition, other studies[17] have shown that HHcy complicated with PE may lead to aggravated pulmonary circulation and unstable hemodynamics by increasing the release of vascular endothelial inflammatory factors.

In this case, the young man had abused N₂O for a long time and had a previous history of peripheral neuropathy. In this patient with no evidence of thrombophilia, PE and DVT were diagnosed successively with the presence of HHcy. Considering his medical history and examination data, we suggested that N₂O abuse was possibly a key link to PE, even though other risk factors for venous thrombosis were present, including lack of exercise, smoking, and obesity.
Although elevated HCY levels can be decreased by 25% by daily use of a folic acid supplement, even at a low dose of 0.5 mg, and by VitB_{6} and B_{12} supplementation, whether this reduces the incidence and recurrence rates of VTE is still controversial. In a case of upper extremity deep vein thrombosis and pulmonary embolism in a patient with methylene tetrahydrofolate reductase deficiency-related HHcy, vitamin and folic acid supplementation were suggested until the levels were in normal ranges. Additionally, in another case of pernicious anemia and HHcy in a patient with a G20210A prothrombin gene mutation, no further episodes of thrombosis occurred after treatment with homocysteine-lowering therapy.

However, a secondary analysis of data from the HOPE-2 trial found that homocysteine-lowering therapy (folic acid, VitB_{6}, and B_{12}) did not significantly reduce the incidence rate of venous thromboembolism [hazard rate (HR): 1.01; confidence interval (CI): 0.66-1.53].

A similar randomized trial enrolling 701 patients showed that vitamin supplementation did not prevent recurrent venous thrombosis (HR: 0.84, 95%CI: 0.56-1.26). We retrospectively reviewed the case of our patient, who had a high risk of drug relapse and a low likelihood of avoiding other risk factors, and we recommended supplementation with folic acid and vitamins to prevent recurrence of VTE.

CONCLUSION

N_{2}O was likely a direct or indirect factor in the pathogenesis of thrombosis in this case, and Hcy played an intermediate role. Furthermore, N_{2}O can cause fatal embolism in severe cases and during the acute stage. We strongly recommend stopping N_{2}O abuse and supplementation with folic acid and vitamins in patients at a high risk of recurrence, although the treatment protocols remain uncertain.
Figure 2 Computed tomographic pulmonary angiography images. A and B (before thrombolysis): The diameter of the left and right pulmonary artery trunks was increased, and there were multiple large filling defects; C and D (5 d after thrombolysis): The extent of filling defect was significantly obviously reduced.

REFERENCES

1. Emmanouil DE, Quock RM. Advances in understanding the actions of nitrous oxide. Anesth Prog 2007; 54: 9-18 [PMID: 17352529 DOI: 10.2344/0003-3006[2007]54[9:AIUTAO]2.0.CO;2]

2. Guyatt GH, Alder EA, Crowther M, Guterman DD, Schünemann HJ; American College of Chest Physicians Antithrombotic Therapy and Prevention of Thrombosis Panel. Executive summary: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed; American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141: 7S-47S [PMID: 22313157 DOI: 10.1378/chest.111722S]

3. Chanarin I. The effects of nitrous oxide on cobalamins, folates, and on related events. Crit Rev Toxicol 1982; 10: 179-213 [PMID: 6127188 DOI: 10.3109/10408448209037455]

4. den Uil SH, Vermeulen EGJ, Metz R, Rijbroek A, de Vries M. Aortic arch thrombus caused by nitrous oxide abuse. J Vasc Surg Cases Innov Tech 2018; 4: 80-82 [PMID: 29942888 DOI: 10.1016/j.jvscit.2018.01.001]

5. Munson ES. Effect of nitrous oxide on the pulmonary circulation during venous air embolism. Anesth Analg 1971; 50: 785-793 [PMID: 5165428 DOI: 10.1213/00000539-197150050-00018]

6. Imberger G, Orr A, Thorlund K, Wetterslev J, Møller AM. Does anaesthesia with nitrous oxide affect mortality or cardiovascular morbidity? A systematic review with meta-analysis and trial sequential analysis. Br J Anaesth 2014; 112: 410-426 [PMID: 24408738 DOI: 10.1093/bja/aet416]

7. Myles PS, Leslie K, Chan MT, Forbes A, Peyton PJ, Paech MJ, Beattie WS, Sessler DI, Devereaux PJ, Silbert B, Schricker T, Wallace S, ANZCA Trials Group for the ENIGMA-II investigators. The safety of addition of nitrous oxide to general anaesthesia in at-risk patients having major non-cardiac surgery (ENIGMA-II): a randomised, single-blind trial. Lancet 2014; 384: 1446-1454 [PMID: 25142708 DOI: 10.1016/S0140-6736(14)60893-X]

8. Cellai AP, Lami D, Antonucci E, Liotta AA, Rogolino A, Fedi S, Fiorillo C, Becatti M, Cenci C, Marcucci R, Abbate R, Frisco D. Hyperhomocysteinemia in patients with pulmonary embolism is associated with impaired plasma fibrinolytic capacity. J Thromb Thrombolysis 2014; 38: 45-49 [PMID: 23963720 DOI: 10.1007/s11239-013-0981-1]

9. Gao L, Kolanuvada B, Naik G, Zhang Y, Zhao M, Sun L, Alaie D, Petrillo RL. Hyperhomocysteinemia-induced upper extremity deep vein thrombosis and pulmonary embolism in a patient with methyltetrahydrofolate reductase mutation: a case report and literature review. Blood Coagul Fibrinolysis 2016; 27: 720-723 [PMID: 26653156 DOI: 10.1097/MBC.0000000000000458]

10. Caldera A, Mora J, Kotler M, Eiger G. Pulmonary embolism in a patient with pernicious anemia and hyperhomocysteinemia. Chest 2002; 122: 1487-1488 [PMID: 12377886 DOI: 10.1378/chest.122.4.1487]

11. Ingrosso D, Cimmino A, Perna AF, Masella L, De Santo NG, De Bonis ML, Vacca M, D’Esposito M, D’Urso M, Galletti P, Zappia V. Folate treatment and unbalanced methylation and changes of allelic expression induced by hyperhomocysteinemia in patients with uraemia. Lancet 2003; 361: 1693-1699 [PMID: 12776735 DOI: 10.1016/S0140-6736(03)13372-7]

12. Ridker PM, Hennekens CH, Selhub J, Miletich JP, Malinow MR, Stampfer MJ. Interrelation of hyperhomocyst(e)inemia, factor V Leiden, and risk of future venous thromboembolism. Circulation 1997; 95: 1777-1782 [PMID: 9107163 DOI: 10.1161/01.cir.95.7.1777]
13 van Guldener C, Stehouwer CD. Hyperhomocysteinaemia and vascular disease—a role for DNA hypomethylation? *Lancet* 2003; 361: 1668-1669 [PMID: 12767729 DOI: 10.1016/S0140-6736(03)13380-6]

14 den Heijer M, Koster T, Blom HJ, Bos GM, Briet E, Reitsma PH, Vandenbroucke JP, Rosendaal FR. Hyperhomocysteinemia as a risk factor for deep-vein thrombosis. *N Engl J Med* 1996; 334: 759-762 [PMID: 8592549 DOI: 10.1056/NEJM199603213341203]

15 Eichinger S, Stümpflen A, Hirsch M, Bialonczyk C, Herkner K, Stain M, Schneider B, Pabinger I, Lechner K, Kyrlle PA. Hyperhomocysteinemia is a risk factor of recurrent venous thromboembolism. *Thromb Haemost* 1998; 80: 566-569 [PMID: 9799979]

16 Taheri SA, Shenoy SS, Mousa S. Circulating soluble tumor necrosis factor receptor as a marker for diagnosis of pulmonary embolus. *J Med* 2001; 32: 163-168 [PMID: 11563814]

17 Lowering blood homocysteine with folic acid based supplements: meta-analysis of randomised trials. Homocysteine Lowering Trialists’ Collaboration. *BMJ* 1998; 316: 894-898 [PMID: 9560391]

18 Ray JG, Kearon C, Yi Q, Sheridan P, Lonn E; Heart Outcomes Prevention Evaluation 2 (HOPE-2) Investigators. Homocysteine-lowering therapy and risk for venous thromboembolism: a randomized trial. *Ann Intern Med* 2007; 146: 761-767 [PMID: 17470822 DOI: 10.7326/0003-4819-146-11-200706050-00157]

19 den Heijer M, Willems HP, Blom HJ, Gerrits WB, Cattaneo M, Eichinger S, Rosendaal FR, Bos GM. Homocysteine lowering by B vitamins and the secondary prevention of deep vein thrombosis and pulmonary embolism: A randomized, placebo-controlled, double-blind trial. *Blood* 2007; 109: 139-144 [PMID: 16960155 DOI: 10.1182/blood-2006-04-014654]
